𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Controlled comparison of nefazodone and amitriptyline in major depressive inpatients

✍ Scribed by Marc Ansseau; Philippe Darimont; Arlette Lecoq; André Nayer; Jean-Luc Evrard; Pierre Krémer; Jean-Michel Devoitille; Michel Dierick; Claudine Mertens; Frans Mesotten; Jean Mirel; Benoît Troisfontaines; Myriam Moffaert; Emilie Vanbrabant

Publisher
Springer
Year
1994
Tongue
English
Weight
925 KB
Volume
115
Category
Article
ISSN
0033-3158

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Controlled comparison of two doses of mi
Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients
✍ Marc Ansseau; Remy Frenckell; Claudine Mertens; Jules Wilde; Louis Botte; Jean-M 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 660 KB

A multicenter study compared the antidepressant efficacy and the tolerance of two doses of milnacipran (50 mg and 100 rag/day) and amitriptyline (150 rag/day) in three parallel groups of 45 major depressive inpatients defined by Research Diagnostic Criteria. After a wash-out period of 4-7 days on pl

Controlled comparison of milnacipran (F2
Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive inpatients
✍ M. Ansseau; R. Von Frenckell; P. Papart; C. Mertens; J. De Wilde; L. Botte; J.-M 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 498 KB

A multicentre study compared the antidepressant efficacy and the tolerance of milnacipran (200 mg/d) and amitriptyline (1 50 mg/d) in two parallel groups of 43 major depressive inpatients, endogenous subtype, as defined by Research Diagnostic Criteria. The duration of the study was 4 weeks, with wee

Controlled comparison of paroxetine and
Controlled comparison of paroxetine and fluvoxamine in major depression
✍ M. Ansseau; A. Gabriëls; J. Loyens; F. Bartholomé; J. L. Evrard; A. De Nayer; R. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 681 KB

A multicentre study compared the antidepressant efficacy and the tolerance of two selective serotonin reuptake inhibitors, paroxetine (20-30 mg/d) and fluvoxamine (50-200 mg/d) in two parallel groups of respectively 56 and 64 patients with major depression, as defined by DSM-III-R criteria. The dura